Zacks: Analysts Expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Will Announce Quarterly Sales of $520,000.00

Wall Street brokerages expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFI – Get Rating) to post $520,000.00 in sales for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Infinity Pharmaceuticals’ earnings. The highest sales estimate is $680,000.00 and the lowest is $200,000.00. Infinity Pharmaceuticals posted sales of $510,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 2%. The business is expected to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Infinity Pharmaceuticals will report full-year sales of $2.05 million for the current year, with estimates ranging from $800,000.00 to $2.70 million. For the next financial year, analysts expect that the company will post sales of $2.17 million, with estimates ranging from $800,000.00 to $3.00 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Infinity Pharmaceuticals.

Infinity Pharmaceuticals (NASDAQ:INFI – Get Rating) last released its quarterly earnings results on Tuesday, May 3rd. The biotechnology company reported ($0.14) EPS for the quarter, hitting the consensus estimate of ($0.14). The company had revenue of $0.65 million for the quarter, compared to analyst estimates of $0.40 million. Infinity Pharmaceuticals had a negative return on equity of 175.11% and a negative net margin of 2,254.97%. During the same quarter in the previous year, the company posted ($0.15) earnings per share.

A number of research analysts have recently issued reports on the company. B. Riley dropped their target price on Infinity Pharmaceuticals from $7.00 to $5.00 in a report on Monday, January 24th. Zacks Investment Research raised Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, March 8th. StockNews.com raised Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, May 15th. Piper Sandler dropped their target price on Infinity Pharmaceuticals from $8.00 to $4.00 and set an “overweight” rating on the stock in a report on Tuesday, March 29th. Finally, Truist Financial dropped their price objective on Infinity Pharmaceuticals from $12.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, March 31st. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $6.39.

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. lifted its position in shares of Infinity Pharmaceuticals by 11.4% in the fourth quarter. BlackRock Inc. now owns 6,667,503 shares of the biotechnology company’s stock valued at $15,001,000 after acquiring an additional 684,014 shares in the last quarter. Polar Capital Holdings Plc purchased a new position in Infinity Pharmaceuticals during the third quarter worth about $8,550,000. State Street Corp lifted its position in Infinity Pharmaceuticals by 4.8% during the first quarter. State Street Corp now owns 1,884,979 shares of the biotechnology company’s stock worth $2,149,000 after buying an additional 86,006 shares during the period. Geode Capital Management LLC lifted its position in Infinity Pharmaceuticals by 22.6% during the third quarter. Geode Capital Management LLC now owns 1,734,032 shares of the biotechnology company’s stock worth $5,930,000 after buying an additional 319,114 shares during the period. Finally, Two Sigma Advisers LP lifted its position in Infinity Pharmaceuticals by 45.3% during the third quarter. Two Sigma Advisers LP now owns 1,693,200 shares of the biotechnology company’s stock worth $5,791,000 after buying an additional 527,800 shares during the period. Institutional investors own 54.74% of the company’s stock.

INFI opened at $0.63 on Friday. The firm has a market cap of $55.86 million, a price-to-earnings ratio of -1.23 and a beta of 2.16. Infinity Pharmaceuticals has a 52 week low of $0.46 and a 52 week high of $3.89. The business’s 50 day moving average is $0.88 and its two-hundred day moving average is $1.47.

Infinity Pharmaceuticals Company Profile (Get Rating)

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors.

Featured Stories